ACE2 and COVID-19: This imbalance between angiotensin II and angiotensin (1–7) is hypothesized to play an essential part in the unfavorable progression of patients with COVID-19 as it may increase inflammation and vasodilation in tissues expressing ACE2 such as the lungs.